InflaRx Revenue and Competitors
Estimated Revenue & Valuation
- InflaRx's estimated annual revenue is currently $5.1M per year.
- InflaRx's estimated revenue per employee is $98,365
- InflaRx's total funding is $64M.
- InflaRx's current valuation is $187.8M. (January 2022)
Employee Data
- InflaRx has 52 Employees.
- InflaRx grew their employee count by 0% last year.
InflaRx's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Medical Officer | Reveal Email/Phone |
2 | Head Marketing | Reveal Email/Phone |
3 | Senior Director, Drug Discovery & Preclinical R&D | Reveal Email/Phone |
4 | Director, Quality Assurance GMP (USA) | Reveal Email/Phone |
5 | Director, Head Programme Management | Reveal Email/Phone |
6 | Senior CMC / Regulatory Manager | Reveal Email/Phone |
7 | Senior Manager Digital Transformation | Reveal Email/Phone |
8 | Senior Medical Science Liaison | Reveal Email/Phone |
InflaRx Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 15 | -32% | N/A | N/A |
#10 | $10.1M | 48 | -9% | N/A | N/A |
What Is InflaRx?
InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007 and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI USA.
keywords:N/A
$64M
Total Funding
52
Number of Employees
$5.1M
Revenue (est)
0%
Employee Growth %
$187.8M
Valuation
N/A
Accelerator
InflaRx News
Form 6-K InflaRx N.V. For: Apr 28. April 28, 2022 4:05 PM. UNITED STATES. SECURITIES AND EXCHANGE COMMISSION. Washington, D.C. 20549...
In November 2021, InflaRx reported positive data from the European Phase II IXCHANGE study of vilobelimab, a first-in-class anti-C5a...
InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary technology to discover and develop...
Other Companies in Jena
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.9M | 53 | 66% | N/A |
#2 | $15.8M | 65 | 5% | N/A |
#3 | $8.9M | 71 | 18% | N/A |
#4 | $14.5M | 75 | -22% | N/A |
#5 | $17.5M | 76 | 13% | N/A |